Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | PPM1B | O75688 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13339539 | 1.00 | TP53 (0.47) | TP53GAASMN1; SMN2CHRNB2CHRNA4 | |
| SCHEMBL6827910 | 1.00 | TP53 (0.47) | TP53GAASMN1; SMN2CHRNB2CHRNA4 | |
| SCHEMBL17453219 | 0.94 | TP53 (0.47) | TP53GAASMN1; SMN2CHRNB2CHRNA4 | |
| SCHEMBL6934192 | 0.88 | EPHX2 (0.36) | TP53GAASMN1; SMN2EPHX2 | |
| SCHEMBL2948892 | 0.87 | TP53 (0.56) | TP53GAASMN1; SMN2CHRNB2CHRNA4 | |
| SCHEMBL244740 | 0.87 | — | — | |
| SCHEMBL74396 | 0.87 | TP53 (0.56) | TP53GAASMN1; SMN2CHRNB2CHRNA4 | |
| SCHEMBL2200767 | 0.87 | TP53 (0.56) | TP53GAASMN1; SMN2CHRNB2CHRNA4 | |
| SCHEMBL21451205 | 0.86 | CHRNB2 (0.44) | TP53GAASMN1; SMN2CHRNB2CHRNA4 | |
| SCHEMBL17802837 | 0.86 | TP53 (0.47) | TP53GAASMN1; SMN2CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240391871-A1 | SUBSTITUTED HYDROXYMETHYL PYRROLIDINES AND MEDICAL USES THEREOF | ATROGI AB (SE) | 2024-11-28 | — | — | US | disclosed |
| US-20240390298-A1 | CYCLOHEXYL BETA-HYDROXY ALKYL AMINES AND MEDICAL USES THEREOF | ATROGI AB (SE) | 2024-11-28 | — | — | US | disclosed |
| EP-4405041-A1 | CYCLOHEXYL BETA-HYDROXY ALKYL AMINES AND MEDICAL USES THEREOF | Atrogi AB (SE) | 2024-07-31 | — | — | EP | disclosed |
| US-20230271940-A1 | HETEROARYL SUBSTITUTED 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2023-08-31 | — | — | US | disclosed |
| US-20230271940-A1 | HETEROARYL SUBSTITUTED 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2023-08-31 | — | — | US | disclosed |
| WO-2023046882-A1 | CYCLOHEXYL BETA-HYDROXY ALKYL AMINES AND MEDICAL USES THEREOF | ATROGI AB (SE) | 2023-03-30 | — | — | WO | disclosed |
| EP-3226688-B1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES | MERCK SHARP & DOHME (US) | 2020-07-01 | — | — | EP | disclosed |
| US-10442819-B2 | Tricyclic compounds as inhibitors of mutant IDH enzymes | MERCK SHARP & DOHME CORP. (US) | 2019-10-15 | — | — | US | disclosed |
| US-10138236-B2 | Factor xia-inhibiting pyridobenzazepine and pyridobenzazocine derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-11-27 | — | — | US | disclosed |
| US-20170369507-A1 | NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES | MERCK SHARP & DOHME CORP. (US) | 2017-12-28 | — | — | US | disclosed |
| US-20170275282-A1 | FACTOR XIA-INHIBITING PYRIDOBENZAZEPINE AND PYRIDOBENZAZOCINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-09-28 | — | — | US | disclosed |
| US-20170275282-A1 | FACTOR XIA-INHIBITING PYRIDOBENZAZEPINE AND PYRIDOBENZAZOCINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-09-28 | — | — | US | disclosed |
| US-20170275282-A1 | FACTOR XIA-INHIBITING PYRIDOBENZAZEPINE AND PYRIDOBENZAZOCINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-09-28 | — | — | US | disclosed |
| WO-2016089797-A1 | NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES | MERCK SHARP & DOHME CORP. (US) | 2016-06-09 | — | — | WO | disclosed |
| WO-2016046157-A1 | FACTOR XIA-INHIBITING PYRIDOBENZAZEPINE AND PYRIDOBENZAZOCINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-03-31 | — | — | WO | disclosed |
| US-8828989-B2 | Oxy-cyclohexyl-4H,6H-5-oxa-2,3,10b-triaza-benzo[E]azulenes as V1A antagonists | HOFFMANN-LA ROCHE INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-20130079333-A1 | OXY-CYCLOHEXYL-4H,6H-5-OXA-2,3,10B-TRIAZA-BENZO[E]AZULENES AS V1A ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-28 | — | — | US | disclosed |
| US-8299060-B2 | Trans-4-[[(5S)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2H-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1H-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid | ELI LILLY AND COMPANY (US) | 2012-10-30 | — | — | US | disclosed |
| US-20120058990-A1 | Trans-4-[[(5S)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2H-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1H-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid | ELI LILLY AND COMPANY (US) | 2012-03-08 | — | — | US | disclosed |
| WO-2010062415-A1 | NITROOXY CYCLOALKANE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2010-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10138236-B2 | Factor xia-inhibiting pyridobenzazepine and pyridobenzazocine derivatives | F13B, TFPI, TFPI2 | TP53 4837/4885GAA 2228/4885SMN1; SMN2 4800/4885 |
| US-20240390298-A1 | CYCLOHEXYL BETA-HYDROXY ALKYL AMINES AND MEDICAL USES THEREOF | H1-5, CYP3A5, HRH3 | TP53 3200/4885GAA 660/4885SMN1; SMN2 2479/4885 |
| US-20240391871-A1 | SUBSTITUTED HYDROXYMETHYL PYRROLIDINES AND MEDICAL USES THEREOF | CYP3A5, PRMT5, CYP11B2 | TP53 2102/4885GAA 1624/4885SMN1; SMN2 1535/4885 |
| US-20230271940-A1 | HETEROARYL SUBSTITUTED 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | XDH, SLCO1B3, ROR1 | TP53 3676/4885GAA 1150/4885SMN1; SMN2 1130/4885 |
| US-10442819-B2 | Tricyclic compounds as inhibitors of mutant IDH enzymes | IDH3A, IDH2, IDH3B | TP53 6/4885GAA 948/4885SMN1; SMN2 3984/4885 |
| US-20120058990-A1 | Trans-4-[[(5S)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2H-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1H-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NT5C, HTR5A | TP53 3280/4885GAA 1462/4885SMN1; SMN2 2911/4885 |
| US-20130079333-A1 | OXY-CYCLOHEXYL-4H,6H-5-OXA-2,3,10B-TRIAZA-BENZO[E]AZULENES AS V1A ANTAGONISTS | AVPR1A, AVPR1B, ADRA2A | TP53 3080/4885GAA 1935/4885SMN1; SMN2 4160/4885 |
| US-20170369507-A1 | NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES | IDH3A, IDH3B, IDH2 | TP53 7/4885GAA 981/4885SMN1; SMN2 3945/4885 |
| US-20170275282-A1 | FACTOR XIA-INHIBITING PYRIDOBENZAZEPINE AND PYRIDOBENZAZOCINE DERIVATIVES | F13B, TFPI, TFPI2 | TP53 4837/4885GAA 2228/4885SMN1; SMN2 4800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.